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BACKGROUND
Aerosolized vaccine can be used as a needle-free method of immunization against 
measles, a disease that remains a major cause of illness and death. Data on the im-
munogenicity of aerosolized vaccine against measles in children are inconsistent.
METHODS
We conducted an open-label noninferiority trial involving children 9.0 to 11.9 months 
of age in India who were eligible to receive a first dose of measles vaccine. Chil-
dren were randomly assigned to receive a single dose of vaccine by means of either 
aerosol inhalation or a subcutaneous injection. The primary end points were sero-
positivity for antibodies against measles and adverse events 91 days after vaccina-
tion. The noninferiority margin was 5 percentage points.
RESULTS
A total of 1001 children were assigned to receive aerosolized vaccine, and 1003 
children were assigned to receive subcutaneous vaccine; 1956 of all the children 
(97.6%) were followed to day 91, but outcome data were missing for 331 children 
because of thawed specimens. In the per-protocol population, data on 1560 of 
2004 children (77.8%) could be evaluated. At day 91, a total of 662 of 775 children 
(85.4%; 95% confidence interval [CI], 82.5 to 88.0) in the aerosol group, as com-
pared with 743 of 785 children (94.6%; 95% CI, 92.7 to 96.1) in the subcutaneous 
group, were seropositive, a difference of −9.2 percentage points (95% CI, −12.2 to 
−6.3). Findings were similar in the full-analysis set (673 of 788 children in the 
aerosol group [85.4%] and 754 of 796 children in the subcutaneous group [94.7%] 
were seropositive at day 91, a difference of −9.3 percentage points [95% CI, −12.3 
to −6.4]) and after multiple imputation of missing results. No serious adverse 
events were attributable to measles vaccination. Adverse-event profiles were simi-
lar in the two groups.
CONCLUSIONS
Aerosolized vaccine against measles was immunogenic, but, at the prespecified 
margin, the aerosolized vaccine was inferior to the subcutaneous vaccine with 
respect to the rate of seropositivity. (Funded by the Bill and Melinda Gates Founda-
tion; Measles Aerosol Vaccine Project Clinical Trials Registry–India number, CTRI/ 
 2009/ 091/ 000673.)
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The Global Vaccine Action Plan aims to eliminate measles from at least five World Health Organization (WHO) regions 
by 2020.1 A safe and effective injectable measles 
vaccine has been widely available since 1963,2 
and intensified efforts between 2000 and 2010 
reduced measles-related deaths by 74%.3 Never-
theless, major outbreaks continue, particularly 
in resource-poor countries that lack investment 
in health care systems and the health service 
infrastructure. In these countries, immunization 
coverage through routine services and mass cam-
paigns remains low.4
New approaches to measles vaccination could 
contribute to reaching elimination goals, particu-
larly if they increase coverage, can be adminis-
tered by people without clinical training, and do 
not cause injection-associated infections.5-7 Aero-
solized vaccine against measles was developed in 
Mexico and has been used in more than 4 mil-
lion children there since 1980.8 Nebulization 
delivers vaccine to the site of natural infection 
and induces measles-specific antibodies and cell-
mediated immunity.9,10
Data about the efficacy of this aerosolized 
vaccine against measles in children are inconsis-
tent, however. Two comprehensive reviews con-
cluded that it was as good as or better than vac-
cine delivered subcutaneously in children 9 months 
of age or older.11,12 However, the two random-
ized, controlled trials comparing these routes of 
administration in children 8 to 13 months of 
age were small, associated with a risk of bias, 
and inconsistent.9,10 A subsequent systematic re-
view pooled data about each route of adminis-
tration from randomized, controlled trials and 
observational studies. Among children 10 to 35 
months of age, the pooled seroconversion rate in 
five studies among those who received aerosol-
ized vaccine against measles was 93.5% (95% 
confidence interval [CI], 89.4 to 97.7), and the 
pooled seroconversion rate in two studies among 
those who received the vaccine subcutaneously 
was 97.1% (95% CI, 92.4 to 100).13 After subcu-
taneous vaccination, approximately 92% (inter-
quartile range, 84 to 96) of children 9 to 10 
months of age and 99% (interquartile range, 93 
to 100) of children 11 to 12 months of age un-
derwent seroconversion.7
Given the established record of injectable 
measles vaccine, alternative delivery methods 
should show noninferiority. A phase 1 trial in 
India of aerosolized vaccine against measles 
showed evidence of safety, immunogenicity, and 
feasibility in children older than 4 years of age 
and in adults.14 In this individually randomized, 
open-label noninferiority trial involving children 
in India, we aimed to compare the immunoge-
nicity and safety of a primary dose of aerosol-
ized vaccine against measles with that of a pri-
mary dose of vaccine delivered subcutaneously.
Me thods
Study Design and Oversight
The WHO Initiative for Vaccine Research coordi-
nated the Measles Aerosol Vaccine Project, and 
the Centers for Disease Control and Prevention 
and the American Red Cross were partners in 
the project. An independent data and safety 
monitoring board had access to unblinded data 
to assess serious adverse events. A product devel-
opment group (see the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org) reviewed progress. Ethics committees 
of the WHO, Christian Medical College (in Vel-
lore, India), the National Institute of Virology, 
and King Edward Memorial Hospital Research 
Centre (in Pune, India) approved the protocol. 
The trial was designed and conducted in accor-
dance with Good Clinical Practice15 and Good 
Laboratory Practice16 guidelines.
The Serum Institute of India provided all vac-
cines free of charge, and Aerogen provided the 
delivery devices free of charge. Additional de-
tails about the trial design, conduct, and analy-
sis are provided in the Supplementary Appendix 
and in the full protocol, including the statistical 
analysis plan, available at NEJM.org.
Study Participants and Clinical Setting
The trial was conducted in villages served by 
eight primary health centers in Pune. One study 
has shown that more than 90% of infants in Pune 
are breast-fed from birth, for a median of 4.7 
months.17 Children between 9.0 and 11.9 months 
of age were eligible to participate in the study if 
they were due to receive primary measles vacci-
nation. Children were excluded from participa-
tion if they were ineligible to receive measles 
vaccine according to WHO criteria.18
Randomization and Vaccination
From December 20, 2009, through April 5, 2010, 
we randomly assigned children, in a 1:1 ratio, to 
receive measles vaccine by means of aerosol in-
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halation or by means of a subcutaneous injec-
tion. A detailed description of the randomiza-
tion process is provided in the Supplementary 
Appendix. After obtaining written informed 
consent from the parents or guardians of the 
children, the study nurses telephoned a central-
ized Web-based service and recorded the study 
assignments. At the Vadu site, which is part of a 
demographic surveillance system,19 two random 
subgroups of 100 children were selected to have 
blood drawn at either day 28 or day 364 for the 
monitoring of serologic responses.
We used a measles vaccine (Serum Institute of 
India), licensed by the WHO, that contained at 
least 1000 viral infective units of the live attenu-
ated Edmonston–Zagreb strain of measles virus 
in each dose. The vaccine was delivered in 10-
dose vials.
The study nurses reconstituted the 10-dose 
vials of measles vaccine and stored them until 
use at 2 to 8°C. They reconstituted the vaccine 
for aerosol delivery in 2-ml diluent and adminis-
tered a single 0.2-ml dose, nebulized for 30 sec-
onds through a single-use nonvented face mask, 
using a battery-operated Aeroneb vibrating mesh 
nebulizer (Aerogen). The nebulizer generated 
aerosol with a volume median diameter of 5.1 μm 
(geometric standard deviation, 2.1 μm) as deter-
mined by means of laser diffraction (Spraytec) 
(details are provided in the Supplementary Ap-
pendix).14 The study nurses reconstituted the 
vaccine for subcutaneous delivery in 5-ml diluent 
and administered a single 0.5-ml dose into the 
left upper arm. The rooms for delivery of aero-
solized vaccine and subcutaneous vaccine were 
separate so that children receiving subcutaneous 
vaccine were not exposed unintentionally to 
aerosolized vaccine. Reconstituted vaccine was 
discarded after 6 hours.
End Points
Immunogenicity
The prespecified primary end point was sero-
positivity for serum antibodies against measles 
91 days after vaccination. We defined seroposi-
tivity as 0.1 or more optical-density units on an 
enzyme-linked immunosorbent assay (ELISA) 
(Enzygnost Anti-Measles Virus/IgG, Siemens) or, 
in samples containing less than 0.1 optical-
density units, a measles antibody concentration 
of 120 mIU per milliliter or more as measured 
with the use of a plaque-reduction neutralization 
test (PRNT). The testing algorithm was based on 
a study that showed a positive predictive value 
of 99.4% for ELISA (cutoff value, 0.1 optical-
density units) as compared with PRNT (cutoff 
value, 120 mIU per milliliter).20
All samples at baseline and day 91 were 
tested by means of ELISA. Specimens with less 
than 0.1 optical-density units and all samples 
from the Vadu site were tested by means of 
PRNT. Paired prevaccination and post-vaccination 
samples were tested in the same run. All speci-
mens were tested at the Virus Reference Depart-
ment, Public Health England (formerly the United 
Kingdom Health Protection Agency), United King-
dom, in March 2012. The specimens had been 
tested in Pune, but the results of a random 10% 
sample of ELISA and PRNT analyses did not meet 
the prespecified quality-assurance criteria, so all 
samples were shipped to the United Kingdom.
Prespecified secondary end points were sero-
conversion and geometric mean concentrations 
of antibodies. Seroconversion was defined as a 
change from seronegative at day 0 to seroposi-
tive at day 91. Secondary outcomes were the 
difference in rates of seroconversion (among 
participants who were seronegative at baseline), 
the ratio of geometric mean concentrations, and 
geometric mean concentrations at days 0, 28, 91, 
and 364 in children in Vadu.
Safety
The prespecified primary safety outcome was 
the frequency of all solicited and unsolicited re-
ports of adverse events up to 91 days after vac-
cination on day 0.21 Study nurses observed all 
children during and for 30 minutes after vacci-
nation. Adverse events were then assessed ac-
cording to the report of parents and guardians 
during home visits on days 3, 7, 10, 17, 21, 28, 
and 56 and by clinical examination on days 14 
and 91 (Fig. S1 in the Supplementary Appendix). 
All children who were enrolled in Vadu were 
evaluated at day 364.
We collected information with the use of 
questionnaires that solicited information on 16 
events (Table S1 in the Supplementary Appendix), 
by means of active surveillance both for events 
requiring treatment or hospitalization and for 
deaths, and through unsolicited reports of events 
from parents or guardians. We sent reports of 
all adverse events to the data and safety moni-
toring board, which had the authority to stop 
the trial if a single serious adverse event was 
judged to be attributable to the vaccine.
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Follow-up and Blinding
We followed all participants until day 91 (from 
March through August 2010, depending on the 
date the patient underwent randomization). 
Case-based active surveillance with serologic con-
firmation of cases of fever and rash (Enzygnost 
Anti-Measles Virus IgM ELISA, Siemens) was in 
place in the entire trial area.22 Parents or guard-
ians, children, and study staff were aware of the 
route of vaccine administration.
To reduce bias, all outcome assessments were 
blinded. Field workers used follow-up case-report 
forms that did not record the vaccination assign-
ment, laboratory staff conducted analyses of coded 
specimens, and statisticians conducted data 
checks and preliminary analyses of blinded data.
Statistical Analysis
We aimed to show that seropositivity after re-
ceipt of aerosolized vaccine against measles was 
no more than 5 percentage points lower than 
seropositivity after subcutaneous vaccination. 
This estimate was based on the 4 percentage-
point difference in a previous systematic review 
of studies involving children 10 to 35 months of 
age13; in addition, with a bigger margin, aerosol-
ized vaccine would not provide levels of protec-
tion required for herd immunity.18
We assumed that exactly 90% of the children 
in each group would be seropositive at day 91, 
and we allowed for lower immunogenicity in 
children younger than 10 months of age.7 For 
noninferiority to be shown with the use of the 
confidence-interval approach, the lower limit of 
the two-sided 95% confidence interval for the 
difference (aerosol group minus subcutaneous 
group) in the proportion of seropositive children 
at day 91 had to be above −5 percentage points 
in the per-protocol population. If the upper con-
fidence interval was below −5 percentage points, 
we would conclude inferiority, and if the lower 
interval was above zero, we would conclude su-
periority (Fig. S2 in the Supplementary Appen-
dix). We estimated that with a sample of 800 
children per group, the study would have 90% 
power to detect these differences. We planned to 
enroll 1000 children per group to allow for 20% 
who would not have results that could be evalu-
ated at follow-up.
We calculated the difference between the 
proportion of children who were seropositive 
after receiving the aerosolized vaccine and the 
proportion who were seropositive after receiving 
the subcutaneous vaccine in the per-protocol 
population (which consisted of children who 
received the assigned vaccine, did not have any 
major protocol deviations, and had specimen 
results at day 91) and the full-analysis popula-
tion (which consisted of all children who under-
went randomization, excluding children for whom 
outcome data were missing). The full-analysis 
population was equivalent to a modified intention-
to-treat population. We used the Wilson score 
method to estimate 95% confidence intervals.23 
Multiple imputation was used to predict sero-
positivity when outcome data were missing, and 
we repeated the analysis with inclusion of all 
participants (see the Supplementary Appendix).24
For the secondary end points, we used logis-
tic regression to investigate the association of 
prespecified factors with lack of seroconversion 
after receipt of aerosolized vaccine. For safety 
outcomes, we calculated the percentages of chil-
dren (with 95% confidence intervals) who had 
any solicited or unsolicited reports of an adverse 
event or serious adverse event up to day 91.
R esult s
Study Participants
In total, 2004 children underwent randomiza-
tion and 1996 received their assigned vaccine 
(Fig. 1). The baseline characteristics of the two 
groups were balanced (Table 1, and Table S3 in 
the Supplementary Appendix). We followed 1956 
of 2004 children (98%) until day 91. Specimens 
obtained from 331 participants (17%) thawed for 
a period during transport and were, therefore, 
excluded from the primary-outcome analyses; 
these specimens were distributed equally be-
tween the aerosol and subcutaneous groups (Fig. 
S3 and Tables S4 and S5 in the Supplementary 
Appendix).
The per-protocol population for the primary 
outcome included 77% of the children (775 of 
1001 children) who were randomly assigned to 
aerosolized vaccine and 78% (785 of 1003 chil-
dren) who were randomly assigned to subcutane-
ous vaccine (Fig. 1). The full-analysis set included 
79% (788 of 1001) of the children who were 
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Figure 1. Eligibility, Randomization, and Follow-up of Children in the Per-Protocol Population.
Data on children in the full-analysis set (788 children in the aerosol group and 796 children in the subcutaneous 
group) are provided in Figure S3 in the Supplementary Appendix; in that analysis, 48 children were lost to follow-up 
before day 91, and data on 331 children with missing laboratory results because of damage to specimens during 
transport were excluded from the analysis of the primary end point. ELISA denotes enzyme-linked immunosorbent 
assay, and PRNT plaque-reduction neutralization test.
2004 Underwent randomization
2384 Children were assessed for eligibility
380 Were excluded
4 Did not meet inclusion criteria
282 Had parents or guardians who declined
to participate
94 Had other reasons
1001 Were assigned to receive measles
aerosolized vaccine
1003 Were assigned to receive subcutaneous
measles vaccine
2 Were excluded
1 Received subcutaneous
vaccine
1 Had parent or guardian
who withdrew consent
6 Were excluded
3 Received aerosolized
vaccine
3 Had parent or guardian
who withdrew consent
999 Received aerosolized vaccine 997 Received subcutaneous vaccine
42 Were excluded
1 Had measles during
follow-up
24 Were lost to follow-up
before day 91
17 Had other protocol
deviations
31 Were excluded
1 Had measles during
follow-up
20 Were lost to follow-up
before day 91
10 Had other protocol
deviations
957 Were followed to day 91 966 Were followed to day 91
182 Were excluded
159 Had specimens that were
damaged in transit
23 Had specimens that
were missing or could
not be analyzed
181 Were excluded
163 Had specimens that were
damaged in transit
18 Had specimens that
were missing or could
not be analyzed
775 Were evaluated for primary outcome
ELISA on day 0, 764 children; day 91, 775 children
PRNT on day 0, 275 children; day 91, 278 children
785 Were evaluated for primary outcome
ELISA on day 0, 767 children; day 91, 785 children
PRNT on day 0, 205 children; day 91, 209 children
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randomly assigned to aerosolized vaccine and 
79% (796 of 1003) of the children who were ran-
domly assigned to subcutaneous vaccine (Fig. S3 
in the Supplementary Appendix). The case-based 
surveillance system in the trial villages identi-
fied 772 confirmed cases of measles from No-
vember 1, 2009, through December 31, 2011.
Laboratory Assays
On the basis of both ELISA and PRNT results 
from day 28 samples obtained from children in 
Vadu, the positive predictive value of the ELISA 
cutoff value of 0.1 optical-density units, as com-
pared with PRNT, was 96% (241 of 250 samples). 
The negative predictive value was 69% (34 of 49 
Characteristic
Aerosolized-
Vaccine Group 
(N = 1001)
Subcutaneous- 
Vaccine Group 
 (N = 1003)
Age — no. (%)
9.0 to <10.0 mo 730 (72.9) 749 (74.7)
10.0 to <11.0 mo 198 (19.8) 165 (16.5)
11.0 to 11.9 mo 73 (7.3) 89 (8.9)
Female sex — no. (%) 488 (48.8) 489 (48.8)
Usual health care provider — no. (%)
Government 184 (18.4) 191 (19.0)
Private 812 (81.1) 802 (80.0)
Other 5 (0.5) 10 (1.0)
Health history — no. (%)†
Preexisting medical condition 2 (0.2) 7 (0.7)
Clinically significant illness in past 3 mo 29 (2.9) 24 (2.4)
Measurements outside normal range for age — no./total no. (%)‡
Height 474/997 (47.5) 480/996 (48.2)
Weight 187/1000 (18.7) 185/1001 (18.5)
Location of primary health care center — no. (%)
Alandi 64 (6.4) 64 (6.4)
Chakan 134 (13.4) 135 (13.5)
Nhavara 155 (15.5) 155 (15.5)
Pabal 130 (13.0) 122 (12.2)
Shel Pimpalgaon 83 (8.3) 84 (8.4)
Talegaon Dhamdhere 63 (6.3) 76 (7.6)
Vadu 191 (19.1) 181 (18.0)
Wagholi 181 (18.1) 186 (18.5)
Measles antibodies at baseline — no. (%)§
Yes 23 (2.3) 16 (1.6)
No 762 (76.1) 768 (76.6)
Could not be evaluated 216 (21.6) 219 (21.8)
*  There were no significant differences in characteristics between the study groups.
†  Preexisting conditions were reported by the parents or guardians of the children and recorded on the case-report form 
(see Table S3 in the Supplementary Appendix).
‡  Recorded values that were greater than 6 SD from the mean were considered by the software package used to calculate 
anthropometric measurements (WHO Anthro, version 3.1.0) to be outliers and were excluded from the analysis.
§  Seropositivity for serum antibodies against measles was defined as 0.1 or more optical-density units on ELISA or, in 
samples containing less than 0.1 optical-density unit, a measles antibody concentration of 120 mIU per milliliter or 
more as measured on the PRNT.
Table 1. Baseline Characteristics of the Participants.*
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samples); this confirmed the need to test sam-
ples that were negative on ELISA with the use of 
PRNT. All samples that were seronegative accord-
ing to PRNT at baseline were also seronegative 
on ELISA.
Immunogenicity
At day 91, a total of 662 of the 775 children in 
the per-protocol population who received aero-
solized vaccine (85.4%; 95% CI, 82.5 to 88.0) and 
743 of the 785 who received subcutaneous vac-
cine (94.6%; 95% CI, 92.7 to 96.1) were sero-
positive, a difference of −9.2 percentage points 
(95% CI, −12.2 to −6.3). The results, based on 
the confidence intervals, did not show noninfe-
riority of aerosolized vaccine to subcutaneous 
vaccine at the 5 percentage-point margin. Aero-
solized vaccine, as compared with subcutaneous 
vaccine, resulted in statistically inferior rates of 
seropositivity (Fig. 2). After multiple imputation 
and with seroconversion as the outcome, results 
in the per-protocol and full-analysis data sets 
were similar (Table S6 in the Supplementary Ap-
pendix). In a sensitivity analysis in which the 
results of damaged specimens were classified as 
being either all seronegative or all seropositive, 
the differences between aerosolized and subcu-
taneous vaccine were smaller but still did not 
show noninferiority of the aerosolized vaccine. 
Among children who were seropositive at day 91, 
geometric mean concentrations were similar in 
the two groups (ratio of the concentration in the 
aerosol group to that in the subcutaneous group, 
1.05; 95% CI, 0.99 to 1.11) (Table S6 in the 
Supplementary Appendix). None of the mea-
sured factors were very strongly associated with 
a lack of seroconversion after the receipt of aero-
solized vaccine (Table S7 in the Supplementary 
Appendix).
Among children in Vadu, geometric mean 
concentrations increased at each time point up 
to 364 days after vaccination in both the aerosol 
and subcutaneous groups (Fig. 3). Between-group 
differences in the proportion of children in Vadu 
who were seropositive (the percentage of chil-
dren who were seropositive in the aerosol group 
minus the percentage of children who were sero-
positive in the subcutaneous group) were as fol-
lows: −0.5 percentage points (95% CI, −5.9 to 4.5) 
on day 0, −24.4 percentage points (95% CI, −36.3 
to −11.8) on day 28, −11.2 percentage points 
(95% CI, −18.3 to −3.9) on day 91, and 1.5 per-
centage points (95% CI, −8.7 to 11.2) on day 364.
Safety
Serious Adverse Events
None of the children died during the trial or the 
follow-up period. By day 91, a total of 38 chil-
dren who had received aerosolized vaccine and 
31 who had received subcutaneous vaccine had 
Figure 2. Immunogenicity Outcomes at Day 91 in the Aerosolized and Subcutaneous Vaccine Groups.
Rates of seropositivity measured in the per-protocol, full-analysis, and multiple-imputation sets and in the two other 
sensitivity analyses are shown. Seroconversion was measured in children who were seronegative for measles anti-
body at day 0 and had a valid result from a serum sample at day 91. The dashed line indicates the noninferiority mar-
gin of 5 percentage points, the squares indicate point estimates, and the I bars indicate 95% confidence intervals.
−5 0 5
Aerosol BetterSubcutaneous Better
Seropositivity (%)
Per-protocol population
Full-analysis population
Multiple-imputation population
Population with data missing on children
assumed to be seronegative
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assumed to be seropositive
Seroconversion (%)
Per-protocol population
Full-analysis population
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Patients
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−15
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had a serious adverse advent (Table 2, and Tables 
S8 and S9 in the Supplementary Appendix). The 
data and safety monitoring board did not judge 
any of the serious adverse events to be probably 
or most probably associated with vaccination 
(Table S8 in the Supplementary Appendix).
Adverse Events
In total, 3776 adverse events from any cause 
(1952 in the aerosol group and 1824 in the sub-
cutaneous group) were recorded up to 91 days 
after vaccination, mostly during three home visits 
in the first 14 days (Table 2, and Tables S9 and 
S10 in the Supplementary Appendix). Adverse-
event profiles in the two groups were similar, 
but coryza was more common among children 
who received aerosolized vaccine (Table 2) 
(P = 0.02). Five adverse effects (rash, coryza, 
cough, diarrhea, and fever) that were reported in 
4 episodes in 2 children in the aerosol group and 
13 episodes in 3 children in the subcutaneous 
group were judged as being probably or most 
probably related to the vaccination.
Discussion
Aerosolized vaccine against measles, as com-
pared with subcutaneously administered vaccine, 
resulted in statistically inferior levels of sero-
positivity at 91 days in children who were 9.0 to 
11.9 months of age. Profiles of adverse events 
were similar in the two groups, and adverse 
events associated with vaccination were rare.
The difference of 9 to 10 percentage points in 
seropositivity between the aerosolized and sub-
cutaneous vaccine was greater than the pre-
specified noninferiority margin of 5 percentage 
points. The narrow noninferiority margin reflect-
ed the need to elicit a high level of seropositivity 
for antibodies against measles, given the estab-
lished record of the licensed subcutaneous vac-
cine.7 The main limitation of our trial was that 
we did not have measles antibody results for 
nearly 20% of the samples; although we followed 
almost all participants to day 91, a batch of 
specimens was damaged during transport. We 
do not believe that this biased our results, how-
ever, because these data were missing at ran-
dom, sensitivity analysis with the use of multiple 
imputation showed that our findings were ro-
bust, and the sample size was adequate because 
the enrollment target allowed for 20% loss to 
follow-up.
The proportion of children who were sero-
positive 91 days after they received aerosolized 
vaccine against measles was 85% (95% CI, 83 to 
88); this proportion was also lower than ex-
pected. Inhibitory maternal antibodies and im-
mature immune systems could have reduced re-
sponses to the measles vaccine,7 but only 2% of 
the children had measles antibodies at enroll-
ment, and seropositivity was similar in older and 
younger children. Furthermore, seropositivity in 
children after receipt of the subcutaneous vac-
cine was in line with published data.7
The proportion of children who were protected 
against measles by aerosolized vaccine could be 
higher than observed because cell-mediated im-
munity is not captured by measurement of neu-
tralizing antibodies. There is no consistent evi-
dence, however, that cell-mediated immunity is 
relatively more important after aerosol vaccina-
tion than after subcutaneous vaccination.10,25 
Prolonging the duration of nebulization to in-
crease the retained dose of aerosolized vaccine 
could increase levels of both neutralizing anti-
bodies and cellular immune responses.25 In the 
subgroup of children tested in Vadu, the geo-
metric mean concentrations increased between 
Figure 3. Geometric Mean Concentrations of Antibod-
ies against Measles, According to Vaccine Group.
Shown are the geometric mean concentrations of anti-
bodies to measles virus as measured on the PRNT in 
children in Vadu who were randomly assigned to aero-
solized or subcutaneous vaccine against measles. 
Specimens were available at days 0, 28, 91, and 364. 
Observations from day 0 and day 91 include all chil-
dren who were enrolled in the trial; observations from 
day 28 and 364 are from randomly selected children. 
Circles and squares indicate point estimates, and  
I bars indicate 95% confidence intervals.
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day 91 and day 364 in children in both trial 
groups. Vaccine-induced antibody levels tend to 
decrease over time, but natural boosting from 
circulating measles virus can result in sustained 
or increasing antibody levels.26 The case-based 
surveillance system showed that measles virus 
was circulating throughout the trial area,22 so 
natural boosting of antibody levels in children in 
both trial groups might have attenuated the dif-
ference in seropositivity by day 364.
The results of this trial are relevant for the 
planning of future research to determine the 
ways in which aerosolized vaccine against mea-
sles could still contribute to further policies and 
goals for measles immunization worldwide.1,18 
First, aerosolized vaccine against measles might 
be effective in older children. In countries that 
have high levels of measles vaccine coverage or 
that are in the elimination phase, primary vac-
cination at 12 months of age is recommended. 
Second, a second dose of a measles-containing 
vaccine is now recommended to protect children 
who did not have a response to the first dose 
and to maintain the 95% level of population im-
Event Aerosolized-Vaccine Group (N = 1002) Subcutaneous-Vaccine Group (N = 998)
No. of 
Adverse 
Events
No. of  
Children with 
Event† % (95% CI)
No. of 
Adverse 
Events
No. of  
Children with 
Event† % (95% CI)
Type of event
Any
Total 1952 644 64.3 (61.2–67.2) 1824 609 61.0 (57.9–64.1)
Probably or most probably related 
to vaccination
4 2 0.2 (0.02–0.7) 13 3 0.3 (0.1–0.9)
Serious
Total 38 38 3.8 (2.7–5.2) 32 31 3.1 (2.1–4.4)
Probably or most probably related 
to vaccination
0 0 0 (0.0–0.4) 0 0 0 (0.0–0.4)
Events of any severity
Anorexia 21 19 1.9 (1.2–3.0) 22 20 2.0 (1.2–3.1)
Conjunctivitis 8 8 0.8 (0.4–1.6) 4 4 0.4 (0.1–1.0)
Coryza‡ 594 441 44.0 (40.9–47.1) 510 386 38.7 (35.6–41.8)
Cough 331 264 26.3 (23.6–29.2) 331 269 27.0 (24.2–29.8)
Crying 39 34 3.4 (2.4–4.7) 30 29 2.9 (2.0–4.2)
Diarrhea 366 282 28.1 (25.4–31.0) 368 286 28.7 (25.9–31.6)
Difficulty breathing 5 4 0.4 (0.1–1.0) 2 2 0.2 (0.02–0.7)
Fever 363 287 28.6 (25.9–31.6) 362 274 27.5 (24.7–30.3)
Irritability 33 29 2.9 (2.0–4.1) 28 24 2.4 (1.6–3.6)
Local reaction 2 2 0.2 (0.02–0.7) 0 0 0 (0.0–0.4)
Malaise 12 11 1.1 (0.6–2.0) 16 14 1.4 (0.8–2.3)
Rash 34 33 3.3 (2.3–4.6) 29 27 2.7 (1.8–3.9)
Seizure 1 1 0.1 (0.0–0.6) 0 0 0 (0.0–0.4)
Shivering 0 0 0.0 (0.0–0.4) 0 0 0 (0.0–0.4)
Vomiting 114 96 9.6 (7.8–11.6) 100 91 9.1 (7.4–11.1)
Wheeze 2 2 0.2 (0.02–0.7) 1 1 0.1 (0.0–0.6)
Others 27 18 1.8 (1.1–2.8) 21 11 1.1 (0.6–2.0)
*  CI denotes confidence interval.
†  Each child could have more than one adverse event
‡  P = 0.02 for the between-group difference.
Table 2. Adverse Events up to Day 91.*
n engl j med 372;16 nejm.org April 16, 20151528
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
munity required to eliminate measles.27 By 2014, 
a total of 145 WHO member states had intro-
duced a two-dose measles vaccination strategy.4 
Aerosolized vaccine against measles induced 
higher and more sustained levels of serologic 
protection than subcutaneous vaccine when ad-
ministered as a second dose in school-age chil-
dren in South Africa.28,29 Third, if aerosolized 
vaccine increases the coverage of primary vacci-
nation, this strategy could be more cost-effective 
than two-dose vaccination at lower levels of 
coverage.30
Data are lacking to evaluate the effectiveness 
and cost-effectiveness of aerosolized vaccine 
against measles as a primary dose in children 
older than 12 months of age and as a second 
dose in children younger than 5 years of age. 
Data are also lacking to evaluate the effective-
ness and cost-effectiveness of aerosolized vaccine 
containing both measles and rubella virus. In 
this randomized, controlled trial, a primary dose 
of aerosolized vaccine against measles in children 
9 months of age or older was immunogenic, but 
at the prespecified margin, the aerosolized vac-
cine was inferior to the subcutaneous vaccine with 
respect to the rate of seropositivity.
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